| Mr Rajiv Malik
| Mr. Malik has served as Mylan’s President since January 1, 2012, before which he was Mylan’s Executive Vice President and Chief Operating Officer since July 2009, Mylan’s Head of Global Technical Operations from January 2007 to July 2009, and Executive Vice President since October 2007. Previously, he served as Chief Executive Officer of Matrix from July 2005 to June 2008. Prior to joining Matrix, he served as Head of Global Development and Registrations for Sandoz GmbH from September 2003 to July 2005. Prior to joining Sandoz, Mr. Malik was Head of Global Regulatory Affairs and Head of Pharma Research for Ranbaxy from October 1999 to September 2003. |
| Ms Heather Bresch
| Ms. Bresch has served as Mylan’s CEO since January 1, 2012, before which she was Mylan’s President since July 2009. She previously served as Mylan’s Executive Vice President and Chief Operating Officer from October 2007 to July 2009, Head of North American Operations from January 2007 to October 2007 and Senior Vice President, Strategic Corporate Development, beginning in February 2006 until January 2007. Ms. Bresch joined Mylan in 1992, and has held a number of management positions, including Vice President, Strategic Corporate Development from May 2005 to February 2006, Vice President of Public and Government Relations from February 2004 to April 2005, Director of Government Relations from March 2002 to February 2004, and Director of Business Development from January 2001 to March 2002. |
| Mr Robert Bailey
| Robert L. Bailey was the Chairman of the Board of Directors of PMC-Sierra ("PMC") from 2005 until May 2011 and also served as PMC's Chairman from February 2000 until February 2003. Mr. Bailey has served as a director of PMC since October 1996. He also served as the President and Chief Executive Officer of PMC from July 1997 until May 2008. PMC is a leading provider of broadband communication and semiconductor storage solutions for the next-generation Internet. Bailey served on the Board of Directors since February 2007. |
| Mr Lawrence Mondry
| Lawrence N. Mondry has served as the Chief Executive Officer of Apollo Brands, a consumer products portfolio company, since February 2014. Prior to that, Mr. Mondry served as Chief Executive Officer of Flexi Campras Corporation from June 2013 to July 2014. Mr. Mondry served as President and Chief Executive Officer of CSK Auto Corporation (“CSK”) from August 2007 to July 2008. Prior to his appointment at CSK, Mr. Mondry served as the Chief Executive Officer of CompUSA Inc. from November 2003 to May 2006. Mr. Mondry joined CompUSA in 1990. Mr. Mondry is the Chairman of the Board's Governance Committee and Compensation Committee. He has served on micron Board of Directors since 2005. |
| Mr Robert E. Switz
| Effective May 26, 2011, the board of directors of GT Advanced Technologies Inc appointed Robert E. Switz as director of the Company. Mr Switz served as a director, President and Chief Executive Officer of ADC Telecommunications, Inc. He is a director of Broadcom Corp since May 28, 2003. From 2003 to 2010 and as its Chairman from 2008 to 2010. ADC Telecommunications, Inc. is a supplier of network infrastructure products and services. Prior to 2003, Mr Switz also served in other positions at ADC Telecommunications, Inc., including as Chief Financial Officer, as well as Executive Vice President and Senior Vice President. Mr Switz also served as President of ADC’s former Broadband Access and Transport Group from November 2000 to April 2001. Prior to joining ADC, Mr Switz was employed by Burr-Brown Corporation, a manufacturer of precision micro-electronics, most recently as Vice President, Chief Financial Officer and Director, Ventures & Systems Business. Mr Switz is also a director of Broadcom Corporation, a manufacturer of networking and communication equipment, and Micron Technology, Inc., a manufacturer of advanced solid state semiconductor solutions. |
| Mr D. Mark Durcan
| Mr. D. Mark Durcan is Chief Executive Officer, Director of Micron Technology Inc. He joined in June 1984 and has served in various positions since that time. Mr. Durcan was appointed our Chief Operating Officer in February 2006, President in June 2007 and Director and Chief Executive Officer in February 2012. Mr. Durcan has been an officer since 1996. Mr. Durcan is a member of the Board of Directors of MWI Veterinary Supply, Inc. and Freescale Semiconductor, Inc. Mr. Durcan holds a BS and MChE in Chemical Engineering from Rice University. Mr. Durcan has served on the Board of Directors since February 2012. |
| Mr Christopher A Sinclair
| Mr Christopher A Sinclair has served as a director of Mattel since 1996. Mr Sinclair served as Chairman of the Board of Scandent Holdings, a Mauritius-based information technology investment company, from 2002 to 2008 and served as Executive Chairman of Cambridge Solutions Corporation Ltd., a leader in providing information technology and business process outsourcing services from 2005 to 2009. He also served as a Managing Director of Manticore Partners, LLC, a venture capital advisory firm, from 2000 to 2005. Prior to that, he served as an Operating Partner of Pegasus Capital Advisors, LP, a private equity firm, from 2000 to 2002. From 1999 to 2000, he served as Chairman of the Board and Chief Executive Officer of Caribiner International, Inc. Prior to that, he served as President and Chief Executive Officer of Quality Food, Inc., Chairman and Chief Executive Officer of Pepsi-Cola Company and President and Chief Executive Officer of PepsiCo Foods & Beverages International and Pepsi-Cola International for more than five years. Mr Sinclair has served on the Board of Directors of several companies: Foot Locker, Inc. (1995-2008, where he served on the Finance and Compensation Committees), Cambridge Solutions Corporation, Ltd. (2003-2009, where he served on the Compensation and Audit Committees), and Perdue Farms (1992-2000). He also serves as Baord Member at Reckitt Benckiser Group PLC. Mr Sinclair holds a bachelor’s degree in Marketing from the University of Kansas and an MBA from the Tuck School of Business at Dartmouth College. |
| Mr Balaji Krishnamurthy
| Mr Balaji Krishnamurthyis Director since 2005. Mr Krishnamurthy is the founder and has served as the President of LogiStyle, a firm that consults with corporations and their boards regarding leadership, corporate culture, governance and strategy, since 2005. From 1999 until 2005, he served as President, Chief Executive Officer and a director of Planar Systems Inc., a provider of flat panel display solutions for the medical, commercial, industrial and retail markets. From 2003 until 2005, he served as the chairman of Planarâs board of directors. Mr. Krishnamurthy held various management, engineering and marketing positions at Tektronix Inc., an electronics manufacturer, from 1984 until 1999 and he is Chief Operations Officer at National Bank of Fujairah psc |
| Ms Catherine Lego
| Ms Catherine P. Lego served as a independent director at the Sandisk Corp from 1989 to 2002 and returned to the Board in May 2004. Ms Lego was a General Partner of The Photonics Fund, an early stage venture fund focused on investing in components, modules and systems companies for the fiber optics telecommunications market from December 1999 to December 2009. She was a general partner at Oak Investment Partners from 1981 to 1992. Ms Lego serves as a director and Chair of the Audit Committee for Lam Research Corporation, a provider of wafer fabrication equipment and services for the semiconductor industry. Ms Lego served as a director and Chair of the Audit Committee for WJ Communications, Inc., a public semiconductor company in the wireless communications market, from October 2004 to May 2008. She also served as a director and chaired the Audit Committee of StrataLight Communication, Inc., a private company which sells optical transport equipment, from September 2007 to January 2009. In March 2011, Ms Lego joined the board of Cosworth Group, a private United Kingdom-based precision engineering products and services company. Ms Lego received a B.A. from Williams College and an M.S. in Accounting from the New York University Graduate School of Business. She has previously practiced as a Certified Public Accountant with Coopers and Lybrand. |
| C. Britt
| Mr. Britt is the President and owner of Carolina Apothecary, Inc., Belmont Pharmacy, Inc. and RxCare, Inc. Mr. Britt has a broad and diverse background of serving on the boards of many organizations, currently including five charitable organizations. He is a graduate of the Directors’ College. Mr. Britt earned a Bachelor of Science degree in Pharmacy from the University of North Carolina at Chapel Hill. |
| Mr Diane B. Greene
| On January 11, 2012, the Board of Directors appointed Diane B. Greene to serve as a member of the Board effective January 12, 2012. Ms. Greene, 56, has been a member of the board of directors of Intuit Inc. since August 2006 and serves on its Audit and Risk Committee and Nominating and Corporate Governance Committee. Ms. Greene co-founded VMware, Inc. in 1998 and took the company public in 2007. She served as Chief Executive Officer and President of VMware from 1998 to 2008, as a member of the board of directors of VMware from 2007 to 2008, and as an Executive Vice President of EMC Corporation from 2005 to 2008. Prior to VMware, Ms. Greene held technical leadership positions at Silicon Graphics Inc., Tandem Computers, Inc., and Sybase Inc., and was Chief Executive Officer of VXtreme, Inc. Ms. Greene is also a member of The MIT Corporation. Ms. Greene holds a Master of Science degree in computer science from the University of California at Berkeley, a Master of Science degree in naval architecture from the Massachusetts Institute of Technology, and a Bachelor of Arts degree in mechanical engineering from the University of Vermont. |
| Mr Lewis Eggebrecht
| Mr. Eggebrecht has been a director of the Company since September 2005. Mr. Eggebrecht joined the Board of Directors as part of the Company’s merger with Integrated Circuit Systems Inc. (ICS), where he had been a director since May 2003. Mr. Eggebrecht served as Vice President and Chief Scientist of ICS from 1998 through May 2003. Mr. Eggebrecht has held various other technical and executive management positions for more than 30 years, including 15 years at IBM as a small systems architect, Phillips Semiconductor as Chief Multimedia Architect, S3 as Graphics Architect, and Commodore and DGM&S as Vice President of Engineering. While at IBM, Mr. Eggebrecht was the Chief Architect and Design Team Leader on the original IBM PC He has also previously served on a number of public and private boards, including currently, as Chairman of the Board for three private companies, BEW Global, an Internet Security company, and LCE Investments and Colorado Restorations, residential and commercial property management companies. Mr. Eggebrecht holds a B.S.E.E. from Michigan Technological University, and has conducted advanced degree studies at Michigan Technological University and the University of Minnesota. Mr. Eggebrecht hold 6 patents on the IBM PC and has authored 2 books on PC architecture, over 20 IBM Technical Disclosure Bulletins and Trade press Articles. Mr. Eggebrecht is a member of NACD and has completed NACD Director Training. |
| Mr Eric Rowinsky
| Eric K. Rowinsky, M.D., has served on Biogen Board of Directors since 2010. Dr. Rowinsky is a member of Biogen Compensation and Management Development Committee, Corporate Governance Committee and Science and Technology Committee. Since January 2012, Dr. Rowinsky has been the Head of Research and Development and Chief Medical Officer of Stemline Therapeutics, Inc., a biotechnology company focusing on the discovery and development of therapeutics targeting cancer stem cells. Dr. Rowinsky is also an adjunct professor of medicine at New York University and has been an independent consultant since January 2010. Prior to that, he was the Chief Medical Officer of Primrose Therapeutics, Inc., a start-up biotechnology company focusing on the development of therapeutics for polycystic kidney disease, from August 2010 until its acquisition in September 2011. From 2005 to December 2009, he served as the Chief Medical Officer and Executive Vice President of ImClone Systems Incorporated, a life sciences company. From 1996 to 2004, Dr. Rowinsky held several positions at the Cancer Therapy & Research Center’s Institute for Drug Development, including Director of the Institute and Director of Clinical Research. During that time, he held the SBC Endowed Chair for Early Drug Development and was Clinical Professor of Medicine at the University of Texas Health Science Center at San Antonio. From 1988 to 1996, Dr. Rowinsky was an associate professor of oncology at the Johns Hopkins School of Medicine and on the staff of the Johns Hopkins Hospital. |
| Mr Stephen Sherwin
| Stephen A. Sherwin, M.D., joined Biogen Board of Directors in 2010. Dr. Sherwin is a member of Biogen Science and Technology Committee, Finance Committee and Risk Committee. Dr. Sherwin currently divides his time between advisory work in the life science industry and patient care and teaching in his specialty of medical oncology. He is a Clinical Professor of Medicine at the University of California, San Francisco, and a volunteer attending physician in hematology-oncology at San Francisco General Hospital. Dr. Sherwin previously served as the Chairman of Ceregene, Inc., a life sciences company that he co-founded, from 2001 until its acquisition by Sangamo BioSciences, Inc., in 2013. He was also co-founder and Chairman of Abgenix, Inc., an antibody company that was acquired by Amgen Inc. in 2006. From 1990 to October 2009, he served as the Chief Executive Officer of Cell Genesys, Inc., a life sciences company, and was its Chairman from 1994 until the company’s merger with BioSante Pharmaceuticals, Inc. in October 2009. Prior to that, he held various positions at Genentech, Inc., a life sciences company, most recently as Vice President, Clinical Research. Dr. Sherwin is board certified in internal medicine and medical oncology and currently serves as a Clinical Professor of Medicine at the University of California, San Francisco. |
| Mr Stelios Papadopoulos
| Stelios Papadopoulos, Ph.D., has served on Biogen Board of Directors since 2008 and was appointed as Chairman in June 2014. He is a member of Biogen Audit Committee, Finance Committee and Science and Technology Committee. Dr. Papadopoulos is the Chairman of the Board of Directors of Exelixis, Inc., a drug discovery and development company that he co-founded in 1994. He is also the Chairman of Regulus Therapeutics, Inc., and a member of the Board of Directors of BG Medicine, Inc., both life sciences companies. He co-founded Anadys Pharmaceuticals, Inc., in 2000 and was a member of its Board of Directors until its acquisition by Hoffman-La Roche in 2011, serving as the Chairman of the board during 2011. In the not-for-profit sector, Dr. Papadopoulos is a co-founder and Chairman of Fondation Santé, a member of the Board of Visitors of Duke Medicine and a member of the Global Advisory Board of the Duke Institute for Health Innovation. |
| Mr Robert Pangia
| Robert W. Pangia has served on Biogen Board of Directors since 1997. Mr. Pangia serves as Chair of Biogen Compensation and Management Development Committee and is a member of Biogen Finance Committee. Mr. Pangia has been the Chief Executive Officer of Ivy Sports Medicine, LLC, a medical device company, since July 2011. He has also been a partner in Ivy Capital Partners, LLC, the general partner of Ivy Healthcare Capital, L.P., a private equity fund specializing in healthcare investments, since 2003. From October 2007 to October 2009, he served as the Chief Executive Officer of Highlands Acquisition Corp., a special-purpose acquisition company. From 1996 to 2003, Mr. Pangia was self-employed as an investment banker. From 1987 to 1996, he held various senior management positions at PaineWebber, a financial services company, including Executive Vice President and Director of Investment Banking for PaineWebber Incorporated of New York, member of the Board of Directors of PaineWebber, Inc., Chairman of PaineWebber Properties, Inc., and member of several of PaineWebber’s executive and operating com |
| Ms Nancy Leaming
| Nancy Leaming joined Biogen Board of Directors in 2008. Ms. Leaming is a member of Biogen Audit Committee and Risk Committee. Ms. Leaming has been an independent consultant since 2005. From 2003 to 2005, she served as the Chief Executive Officer and President of Tufts Health Plan, a provider of healthcare insurance. From 1986 to 2003, Ms. Leaming served in several executive positions at Tufts Health Plan, including President, Chief Operating Officer and Chief Financial Officer. Ms. Leaming is also a member of the Boards of Directors of Hologic, Inc., a provider of diagnostic and surgical products, and Edgewater Technology, Inc., a technology management consulting firm. |
| Mr Kevin Lofton
| Kevin E. Lofton, age 57, joined our Board in July 2009. He is currently the President and Chief Executive Officer of Catholic Health Initiatives, a Denver-based healthcare system operating the full continuum of services from hospitals to home health agencies throughout the nation. He previously served as Chief Executive Officer of two university hospitals, the University of Alabama at Birmingham Hospital and Howard University Hospital in Washington, D.C. In 2007, Mr. Lofton served as Chairman of the Board of the American Hospital Association, the nation’s largest hospital trade association. Mr. Lofton also serves on the Board of Directors of the Morehouse School of Medicine, Atlanta, and the Georgia State University J. Mack Robinson College of Business, also in Atlanta. |
| Ms Robin Washington
| Ms. Robin Washington is the Senior Vice President and Chief Financial Officer of Gilead Sciences, Inc. , a biopharmaceutical company, since May 2008. From 2006 to 2007, Ms. Washington was Chief Financial Officer of Hyperion Solutions, a business performance management software company, which was acquired by Oracle Corporation in March 2007. From 1986 to 2005, Ms. Washington served in a number of executive positions with PeopleSoft , a software company focused on human resource management, financial management, and customer relationship management products, most recently in the role of Senior Vice President and Corporate Controller. From May 2005 to November 2007, Ms. Washington served on the board of directors of Tektronix, Inc. (which was acquired by Danaher). Ms. Washington joined the Company’s Board of Directors in April 2008 |
| Mr Richard Whitley
| Richard J. Whitley, age 66, joined Gilead Board in July 2008. He also serves as the Distinguished Professor, Loeb Scholar Chair in Pediatrics; Director, Division of Pediatric Infectious Diseases; Vice-Chair, Department of Pediatrics; Senior Scientist, Department of Gene Therapy; Senior Scientist, Cancer Research and Training Center; Associate Director for Clinical Studies, Center for AIDS Research; and Co-Director, Center for Emerging Infections and Emergency Preparedness (CEIEP) for the University of Alabama at Birmingham. Dr. Whitley has held responsibility for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group, is a former President of the International Society of Antiviral Research, chairs the Board of Scientific Councilors for the National Center for Infectious Diseases of the U.S. Centers for Disease Control and Prevention and is President of the Board of the Infectious Disease Society of America. |
